|
| 37889114 | PHF6-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax. | Clin Cancer Res | 2024 |
| 36376378 | Gilteritinib activity in refractory or relapsed FLT3-mutated acute myeloid leukemia patients previously treated by intensive chemotherapy and midostaurin: a study from the French AML Intergroup ALFA/FILO. | Leukemia | 2023 |
| 37595275 | Genetic alterations and MRD refine risk assessment for KMT2A-rearranged B-cell precursor ALL in adults: a GRAALL study. | Blood | 2023 |
| 37604981 | Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial. | Leukemia | 2023 |
| 36951156 | Survival outcomes with oral azacitidine maintenance in patients with acute myeloid leukemia in remission by receipt of initial chemotherapy: subgroup analyses from the phase III QUAZAR AML-001 trial. | Haematologica | 2023 |
| 36951151 | Allogeneic transplantation in acute myelogenous leukemia: a comprehensive single institution's experience. | Haematologica | 2023 |
| 37085611 | UBTF tandem duplications define a distinct subtype of adult de novo acute myeloid leukemia. | Leukemia | 2023 |
| 37116523 | Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial. | Lancet | 2023 |
| 37205853 | LSC17 score complements genetics and measurable residual disease in acute myeloid leukemia: an ALFA study. | Blood Adv | 2023 |
| 37430263 | TREC mediated oncogenesis in human immature T lymphoid malignancies preferentially involves ZFP36L2. | Mol Cancer | 2023 |
| 36655608 | Long-term survival with oral azacitidine for patients with acute myeloid leukemia in first remission after chemotherapy: Updated results from the randomized, placebo-controlled, phase 3 QUAZAR AML-001 trial. | Am J Hematol | 2023 |
| 36650499 | Harnessing the MYB-dependent TAL1 5'super-enhancer for targeted therapy in T-ALL. | Mol Cancer | 2023 |
| 36773040 | Benefits of dexamethasone on early outcomes in patients with acute myeloid leukemia with hyperleukocytosis: a propensity score matched analysis. | Ann Hematol | 2023 |
| 36630200 | Adult Low-Hypodiploid Acute Lymphoblastic Leukemia Emerges from Preleukemic TP53-Mutant Clonal Hematopoiesis. | Blood Cancer Discov | 2023 |
| 36891751 | Impact of central nervous system involvement in adult patients with Philadelphia-negative acute lymphoblastic leukemia: a GRAALL-2005 study. | Haematologica | 2023 |
| 34615986 | Machine learning identifies the independent role of dysplasia in the prediction of response to chemotherapy in AML. | Leukemia | 2022 |
| 35443031 | Prognostic impact of DDX41 germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study. | Blood | 2022 |
| 35474100 | Cystine uptake inhibition potentiates front-line therapies in acute myeloid leukemia. | Leukemia | 2022 |
| 35767897 | International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. | Blood | 2022 |
| 35797463 | Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. | Blood | 2022 |
| 35456626 | Daunorubicin and Its Active Metabolite Pharmacokinetic Profiles in Acute Myeloid Leukaemia Patients: A Pharmacokinetic Ancillary Study of the BIG-1 Trial. | Pharmaceutics | 2022 |
| 35750691 | A multiparametric niche-like drug screening platform in acute myeloid leukemia. | Blood Cancer J | 2022 |
| 35618837 | A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia. | Nat Med | 2022 |
| 36431240 | Preclinical Evaluation of a Novel Small Molecule Inhibitor of LIM Kinases (LIMK) CEL_Amide in Philadelphia-Chromosome Positive (<i>BCR::ABL+</i>) Acute Lymphoblastic Leukemia (ALL). | J Clin Med | 2022 |
| 36570694 | Relative Mitochondrial Priming Predicts Survival in Older AML Patients Treated Intensively. | Hemasphere | 2022 |
| 36494771 | Publisher Correction: Frugal alignment-free identification of FLT3-internal tandem duplications with FiLT3r. | BMC Bioinformatics | 2022 |
| 35872338 | Characteristics and clinical outcomes of SARS-CoV-2 infection in adult patients with acute leukemia in France. | Leuk Res | 2022 |
| 36307762 | Frugal alignment-free identification of FLT3-internal tandem duplications with FiLT3r. | BMC Bioinformatics | 2022 |
| 36201165 | Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience. | Clin Cancer Res | 2022 |
| 35960871 | Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine. | Blood | 2022 |
| 34983928 | Author Correction: Genome-wide association study identifies susceptibility loci for acute myeloid leukemia. | Nat Commun | 2022 |
| 35316324 | Concurrent CDX2 cis-deregulation and UBTF::ATXN7L3 fusion define a novel high-risk subtype of B-cell ALL. | Blood | 2022 |
| 35072371 | The Evolution of Research and Therapy With Hypomethylating Agents in Acute Myeloid Leukemia and Myelodysplastic Syndrome: New Directions for Old Drugs. | Cancer J | 2022 |
| 35008099 | Prognostic impact of ABCA3 expression in adult and pediatric acute myeloid leukemia: an ALFA-ELAM02 joint study. | Blood Adv | 2022 |
| 34995344 | Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status. | Blood | 2022 |
| 35263986 | High tumor burden before blinatumomab has a negative impact on the outcome of adult patients with B-cell precursor acute lymphoblastic leukemia. A real-world study by the GRAALL. | Haematologica | 2022 |
| 35082269 | Clinico-biological features of T-cell acute lymphoblastic leukemia with fusion proteins. | Blood Cancer J | 2022 |
| 34895843 | Antifungal Prophylaxis in AML Patients Receiving Intensive Induction Chemotherapy: A Prospective Observational Study From the Acute Leukaemia French Association (ALFA) Group. | Clin Lymphoma Myeloma Leuk | 2022 |
| 32581253 | Clonal dominance is an adverse prognostic factor in acute myeloid leukemia treated with intensive chemotherapy. | Leukemia | 2021 |
| 33881523 | Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML: an ALFA study. | Blood | 2021 |
| 33596765 | Data from French named patient program of quizartinib in relapsed/refractory acute myeloid leukemia. | Leuk Lymphoma | 2021 |
| 33564120 | Outcomes following hematopoietic stem cell transplantation in patients treated with standard chemotherapy with or without gemtuzumab ozogamicin for acute myeloid leukemia. | Bone Marrow Transplant | 2021 |
| 33564086 | Correction to: Allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia or myelodysplastic syndromes: myth and reality. | Leukemia | 2021 |
| 34410352 | Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy. | Blood | 2021 |
| 34551506 | Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: results from the phase 3, placebo-controlled QUAZAR AML-001 trial. | Haematologica | 2021 |
| 34625784 | Early detection of WT1 measurable residual disease identifies high-risk patients, independent of transplantation in AML. | Blood Adv | 2021 |
| 34454540 | Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial. | J Hematol Oncol | 2021 |
| 34476345 | The EHA Research Roadmap: Malignant Myeloid Diseases. | Hemasphere | 2021 |
| 33941203 | Oncogenetic landscape and clinical impact of IDH1 and IDH2 mutations in T-ALL. | J Hematol Oncol | 2021 |
| 34301789 | Actinomycin D Targets NPM1c-Primed Mitochondria to Restore PML-Driven Senescence in AML Therapy. | Cancer Discov | 2021 |